Actively Recruiting
Adjuvant Treatment Outcomes in Premenopausal Women With Early Breast Cancer Evaluated by Oncotype DX Test
Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2026-09-03
800
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This observational study focuses on premenopausal women diagnosed with early-stage breast cancer who have undergone the 21-gene Oncotype DX assay between January 1, 2013, and December 31, 2022. The research collects information on tumor characteristics, genomic profiles, nodal status, and adjuvant treatments to understand outcomes in this patient group. The goal is to assess invasive disease-free survival over five years and describe how treatments relate to clinical and genomic risk. Participants include women with hormone-positive, HER2-negative breast cancer with either no nodal involvement pN0 or limited nodal involvement pN1 and tumors staged from pT1 to pT3. Data gathered includes results from the Oncotype DX assay, surgery details, adjuvant chemotherapy, endocrine therapy with or without ovarian function suppression, and survival outcomes. Patients are grouped based on nodal status and recurrence scores. During the study, researchers review clinical, pathological, and genomic data along with treatment records and patient outcomes such as relapse and survival information. The primary measurement is invasive disease-free survival at five years, with follow-up data collected up to 30 months. This long-term observational period allows assessment of treatment effects and disease progression. Participants involvement mainly consists of data collection from past clinical records without active treatment or intervention during the study.
CONDITIONS
Brief Title
Adjuvant Treatment in Premenopausal Breast Cancer
Research Team
C
Clinical Research Technology
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here